Sandoz says new clinical data support two biosimilars
ZURICH (Reuters) - Novartis' generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Health | Humira | Psoriasis | Rituxan | Study